Tamminga, Cindy <br/><br/>
Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component.  [electronic resource] 

 -  PloS one  2011 
 - e25868 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0025868  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenoviridae--genetics<br/>Adolescent<br/>Adult<br/>Antigens, Protozoan--adverse effects<br/>Dose-Response Relationship, Immunologic<br/>Female<br/>Gene Expression<br/>Genetic Vectors--genetics<br/>Humans<br/>Malaria Vaccines--adverse effects<br/>Male<br/>Membrane Proteins--adverse effects<br/>Middle Aged<br/>Plasmodium falciparum--cytology<br/>Protozoan Proteins--adverse effects<br/>Sporozoites--immunology<br/>Young Adult